메타바이오메드
3,815KRWMarket close of 10/21 (Wed)
Up +0.13%+5KRWMarket close of 10/21 (Wed)
- Open
- 3,810
- High
- 3,845
- Low
- 3,790
- Day range
- Day range low 3,790 high 3,845, open 3,810, close 3,815, previous close 3,810
- Volume
- 5×10K shares
- 200.73 million KRW 0.66× the 20-session average
Market close of 10/21 (Wed)
Where it sits in the 1-year range
14%1-year close range 3,385 to 6,390 won, 14% up from the low
14% of the way up from the lowest close in 1 year (252 sessions) · -40.3% from the high
Usual range
Nothing unusual in the 4 checked items
Free · no sign-inSource from 2021-05-17
Points to check
- Recent filingsnot verifiedOutside filing data coverage, so not verified
- Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified
- Daily moveusual range+0.13%+0.13%, 0.1× the usual (20-session average ±1.19%)That day +0.13% · usual ±1.19% · large-move threshold ±3.0%
The other 3 are within the usual range
- Trading value0.7×usual range
- EarningsOperating income, 8 quarters
- Data date10/21 (Wed)Market close
See the full check report
Quarterly results · Q1 2026
- Revenue24.4B KRW
- vs. year ago
- -11.8%
- vs. prior quarter
- -6.9%
- Operating income4.9B KRW
- vs. year ago
- -13.6%
- vs. prior quarter
- +65.1%
- Operating margin19.9%
- vs. year ago
- -0.4 pp
- vs. prior quarter
- +8.7 pp
Quarterly operating income trend
As of the latest official close · 2026-10-21Valuation filing date · 2026-06-29Same sector · 제약
Up +0.83%· 57 of 168 stocks up, preferred shares excluded · trading value 730.8B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 삼성바이오로직스 | Close over the last 20 sessions +1.5% | Up +1.87% | 166.1B KRW |
| 셀트리온 | Close over the last 20 sessions +9.6% | Up +0.10% | 119.2B KRW |
| 지투지바이오 | Close over the last 20 sessions +27.6% | Up +13.78% | 49.8B KRW |
| 삼익제약 | Close over the last 20 sessions -20.3% | Up +2.58% | 47.2B KRW |
| 유한양행 | Close over the last 20 sessions +11.7% | Up +0.46% | 35.3B KRW |
Schedule
- Next data 10/23 (Fri) after 08:50
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 85% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.